AzTrials
AzTrials

HealthyNCT07043478

A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

A study testing Bragg ACV Liquid in people with Healthy and Blood Glucose, run by Bragg Live Food Products at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Healthy, Blood Glucose
What is being tested?
Bragg ACV Liquid
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
24 participants
Where
1 siteCanada
Study dates
5 Aug 2025to 22 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Males and females 20 - 50 years of age, inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
  • Or,
  • Individuals of child-bearing potential must have a negative screening urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Double-barrier method
  • Intrauterine devices
Show all 13Show fewer
  • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
  • Vasectomy of partner at least 6 months prior to screening
  • Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Subjects with elevated fasting glucose > 5.6 mmol/L (> 100 mg/dL) and < 7.0 mmol/L (< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:
  • Abdominal obesity: waist circumference > 102 cm (40 inches) in men and > 88 cm (35 inches) in women
  • Hypertension: systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg
  • Elevated TG: > 150 mg/dL (1.7 mmol/L)
  • Low HDL-C: < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.29 mmol/L) in women 4. Stable body weight defined as a <5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI) 5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 6. Agrees to comply with dietary guidelines and study requirements prior to in-clinic visits (see Section 9.1) 7. Provided voluntary, written, informed consent to participate in the study 8. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)

Who cannot join

  • Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  • Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
  • Poor venous access as assessed by the QI
  • Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
  • Unstable metabolic disease or chronic diseases as assessed by the QI
  • Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
Show all 25Show fewer
  • Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  • Type I or Type II diabetes
  • Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  • History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  • Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  • Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  • Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  • Individuals with an autoimmune disease or are immune compromised as assessed by the QI
  • Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
  • Self-reported confirmation of blood/bleeding disorders as assessed by the QI
  • Chronic inhalation or edible use of cannabinoid products (>1 time/month). Occasional users must agree to abstain from use while participating in the study
  • Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
  • Alcohol intake average of >2 standard drinks per day as assessed by the QI
  • Alcohol or drug abuse within the last 12 months
  • Clinically significant abnormal laboratory results at screening as assessed by the QI
  • Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  • Participation in other clinical research studies 30 days prior to baseline as assessed by the QI
  • Individuals who are unable to give informed consent
  • Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • KGK Science Inc.

    London, Ontario, N6B3L1

Other trials in Canada

About this study

Official title: A Randomized, Single-blind, Controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is:

Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load.

Participants will [describe the main tasks participants will be asked to consume 750 mg of Bragg Apple Cider Vinegar (ACV) liquid or water and undergo a blood draw to measure glucose, insulin, and future analysis markers.

Being tested
Bragg ACV Liquid, Placebo
Keywords
Blood glucose control, Bragg Apple Cider Vinegar, Apple Cider Vinegar

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bragg ACV LiquidOther

    Apple Cider Vinegar

  • PlaceboOther

    Water

Study groups in NCT07043478
Study groupRoleWhat they receive
Bragg ACV LiquidExperimentalApple Cider Vinegar (1 tablespoon) will be consumed
Receives: Other: Bragg ACV Liquid
PlaceboExperimentalWater (4 ounces) will be consumed
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The difference in the iAUC(0 - 120 min) for venous blood glucose concentration between Bragg ACV liquid and placebo following an acute carbohydrate load

    The difference in the iAUC(0 - 120 min) for venous blood glucose concentration between Bragg ACV liquid and placebo following an acute carbohydrate load

    Measured: Up to 120 minutes

Secondary outcomes (5)

  1. The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the maximum concentration (Cmax) for venous blood glucose concentration

    The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the maximum concentration (Cmax) for venous blood glucose

    Measured: Up to 120 minutes

  2. The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the time of maximum concentration (Tmax) for venous blood glucose concentration

    The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the time of maximum concentration (Tmax) for venous blood glucose concentration

    Measured: 0 to Tmax, assessed up to 120 minutes

  3. The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the AUC(0 - 120 min) for serum insulin

    The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the AUC(0 - 120 min) for serum insulin

    Measured: Up to 120 minutes

  4. The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the Cmax for serum insulin

    The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the Cmax for serum insulin

    Measured: Up to 120 minutes

  5. The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the Tmax for serum insulin

    The difference between Bragg ACV liquid and placebo following an acute carbohydrate load in the Tmax for serum insulin

    Measured: 0 to Tmax, assessed up to 120 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2025
  2. Study start5 Aug 2025
  3. Primary completion22 Mar 2026
  4. Study completion22 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07043478
Sponsor's protocol ID
25BGCFC01
Status last verified
Jul 2026
First submitted
10 Jun 2025
Last updated
8 Jul 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Bragg ACV Liquid in people with Healthy and Blood Glucose, run by Bragg Live Food Products at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The difference in the iAUC(0 - 120 min) for venous blood glucose concentration between Bragg ACV liquid and placebo following an acute carbohydrate load (time frame: Up to 120 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07043478.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in